Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

ObjectivesRegorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-...

Full description

Bibliographic Details
Main Authors: Faysal Dane, Kirhan Ozgurdal, Şuayib Yalçın, Mustafa Benekli, Nuri Faruk Aykan, İdris Yücel, Metin Özkan, Turkkan Evrensel, Alper Sevinç, Hasan Şenol Coskun, Ulus Ali Sanli, Ismail Oguz Kara, Perran Fulden Yumuk
Format: Article
Language:English
Published: BMJ Publishing Group 2020-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/3/e027665.full

Internet

https://bmjopen.bmj.com/content/10/3/e027665.full

Similar Items